US Patent

US11806321 — Non-linear dosing of mirdametinib

Method of Use · Assigned to SpringWorks Therapeutics Inc · Expires 2041-02-17 · 15y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a method of using mirdametinib to treat certain types of tumors or cancers, such as plexiform neurofibromas.

USPTO Abstract

The present disclosure relates to methods for treating certain types of tumors or cancers, such as plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), by administering to a patient in need thereof mirdametinib or a pharmaceutically acceptable salt thereof, such as by a certain dosing scheme.

Drugs covered by this patent

mirdametinib (MIRDAMETINIB)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4130`	—	mirdametinib
`U-4130`	—	mirdametinib
`U-4130`	—	mirdametinib

Patent Metadata

Patent number: US11806321
Jurisdiction: US
Classification: Method of Use
Expires: 2041-02-17
Drug substance claim: No
Drug product claim: No
Assignee: SpringWorks Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.